Cargando…

A meta-analysis of wenxin granule and metoprolol for the treatment of coronary heart disease and arrhythmia

This meta-analysis aimed to systematically and comprehensively assess the effectiveness and safety of wenxin granule (WXG) and metoprolol in the treatment of elderly patients with coronary heart disease (CHD) and arrhythmia. METHODS: We searched the electronic databases of the Cochrane Library, PUBM...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Ling-Li, Huang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439832/
https://www.ncbi.nlm.nih.gov/pubmed/36107542
http://dx.doi.org/10.1097/MD.0000000000030250
_version_ 1784782164796112896
author Meng, Ling-Li
Huang, Wei
author_facet Meng, Ling-Li
Huang, Wei
author_sort Meng, Ling-Li
collection PubMed
description This meta-analysis aimed to systematically and comprehensively assess the effectiveness and safety of wenxin granule (WXG) and metoprolol in the treatment of elderly patients with coronary heart disease (CHD) and arrhythmia. METHODS: We searched the electronic databases of the Cochrane Library, PUBMED, EMBASE, CNKI, Wangfang, and CBM from initiation to May 1, 2022, and selected a set of clinical indicators for WXG and metoprolol for CHD and arrhythmia. The methodological quality of the included studies was analyzed using the Cochrane risk-of-bias tool. Data were pooled using a fixed-effects or random-effects model, and a meta-analysis was conducted. RESULTS: Eight randomized controlled trials involving 722 patients with CHD and arrhythmia were included. Our findings showed that WXG and metoprolol showed better effects than metoprolol alone on electrocardiogram change (odds ratio [OR] = 7.21, 95% confidence interval [CI] [1.48, 35.07]), clinical symptom improvement (OR = 5.83, 95% CI [1.52, 22.35]), overall clinical effect (OR = 5.51, 95% CI [2.65, 11.44], P < .001), atrial premature beat (mean difference [MD] = −109.85, 95% CI [−171.25, −48.46], P < .001), ventricular premature beat (MD = −195.43, 95% CI [−334.09, −56.77], P < .001), borderline premature beat (MD = −42.92, 95% CI [−77.18, −8.67], P = .01), short-burst ventricular tachycardia (MD = −35.98, 95% CI [−39.66, −32.30], P < .001), ST segment reduction (MD = −0.47, 95% CI [−0.54, −0.40], P < .001), ST segment decrease duration (MD = −0.76, 95% CI [−0.95, −0.57], P < .001). However, no significant differences were observed in adverse reactions (OR = 0.54, 95% CI [0.27, 1.09], P = .09). CONCLUSION: Compared to metoprolol alone, WXG and metoprolol can more effectively manage patients with CHD and arrhythmia. However, additional large-scale, multicenter, rigorous, and high-quality randomized controlled trials are warranted to verify the present findings.
format Online
Article
Text
id pubmed-9439832
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94398322022-09-06 A meta-analysis of wenxin granule and metoprolol for the treatment of coronary heart disease and arrhythmia Meng, Ling-Li Huang, Wei Medicine (Baltimore) Research Article This meta-analysis aimed to systematically and comprehensively assess the effectiveness and safety of wenxin granule (WXG) and metoprolol in the treatment of elderly patients with coronary heart disease (CHD) and arrhythmia. METHODS: We searched the electronic databases of the Cochrane Library, PUBMED, EMBASE, CNKI, Wangfang, and CBM from initiation to May 1, 2022, and selected a set of clinical indicators for WXG and metoprolol for CHD and arrhythmia. The methodological quality of the included studies was analyzed using the Cochrane risk-of-bias tool. Data were pooled using a fixed-effects or random-effects model, and a meta-analysis was conducted. RESULTS: Eight randomized controlled trials involving 722 patients with CHD and arrhythmia were included. Our findings showed that WXG and metoprolol showed better effects than metoprolol alone on electrocardiogram change (odds ratio [OR] = 7.21, 95% confidence interval [CI] [1.48, 35.07]), clinical symptom improvement (OR = 5.83, 95% CI [1.52, 22.35]), overall clinical effect (OR = 5.51, 95% CI [2.65, 11.44], P < .001), atrial premature beat (mean difference [MD] = −109.85, 95% CI [−171.25, −48.46], P < .001), ventricular premature beat (MD = −195.43, 95% CI [−334.09, −56.77], P < .001), borderline premature beat (MD = −42.92, 95% CI [−77.18, −8.67], P = .01), short-burst ventricular tachycardia (MD = −35.98, 95% CI [−39.66, −32.30], P < .001), ST segment reduction (MD = −0.47, 95% CI [−0.54, −0.40], P < .001), ST segment decrease duration (MD = −0.76, 95% CI [−0.95, −0.57], P < .001). However, no significant differences were observed in adverse reactions (OR = 0.54, 95% CI [0.27, 1.09], P = .09). CONCLUSION: Compared to metoprolol alone, WXG and metoprolol can more effectively manage patients with CHD and arrhythmia. However, additional large-scale, multicenter, rigorous, and high-quality randomized controlled trials are warranted to verify the present findings. Lippincott Williams & Wilkins 2022-09-02 /pmc/articles/PMC9439832/ /pubmed/36107542 http://dx.doi.org/10.1097/MD.0000000000030250 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle Research Article
Meng, Ling-Li
Huang, Wei
A meta-analysis of wenxin granule and metoprolol for the treatment of coronary heart disease and arrhythmia
title A meta-analysis of wenxin granule and metoprolol for the treatment of coronary heart disease and arrhythmia
title_full A meta-analysis of wenxin granule and metoprolol for the treatment of coronary heart disease and arrhythmia
title_fullStr A meta-analysis of wenxin granule and metoprolol for the treatment of coronary heart disease and arrhythmia
title_full_unstemmed A meta-analysis of wenxin granule and metoprolol for the treatment of coronary heart disease and arrhythmia
title_short A meta-analysis of wenxin granule and metoprolol for the treatment of coronary heart disease and arrhythmia
title_sort meta-analysis of wenxin granule and metoprolol for the treatment of coronary heart disease and arrhythmia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439832/
https://www.ncbi.nlm.nih.gov/pubmed/36107542
http://dx.doi.org/10.1097/MD.0000000000030250
work_keys_str_mv AT menglingli ametaanalysisofwenxingranuleandmetoprololforthetreatmentofcoronaryheartdiseaseandarrhythmia
AT huangwei ametaanalysisofwenxingranuleandmetoprololforthetreatmentofcoronaryheartdiseaseandarrhythmia
AT menglingli metaanalysisofwenxingranuleandmetoprololforthetreatmentofcoronaryheartdiseaseandarrhythmia
AT huangwei metaanalysisofwenxingranuleandmetoprololforthetreatmentofcoronaryheartdiseaseandarrhythmia